Ann: Allied's Herpes Vaccine Progresses to Ph, page-93

re: Ann: Allied's Herpes Vaccine Progress... The things holding AHZ back at the moment :
-The wider markets pullback.
-A few short term traders locking in recent strong gains
-Some end of tax year selling.

In short, nothing company specific.

I find it quite stunning really, that AHZ has not received more analyst attention. Their story is the most compelling out of all the biotechs in Australia. I see very little downside, due to their existing medical product revenue, which is building steadily. Cardiocel could produce a 10 bagger from here and HPV vaccines could see it shoot to the moon.

Where are the professional analysts on this?

I realise that historically Aus has a commodity focus, but those analysts must now be scratching around and getting worried about their jobs! They need to sharpen their pencils, get the medical journals out and apply their minds to the biotech space because this is where it's at, and AHZ is in the box seat.